Cowen and Company’s Aurinia Pharmaceuticals AUPH Stock Holding History

Cowen and Company’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-13,000	Closed	-$25K	–	592
2021 Q2	$25K	Sell	13,000 -12,000	-48%	-$153K	﹤0.01%	465
2021 Q1	$52K	Sell	25,000 -29,400	-54%	-$427K	﹤0.01%	383
2020 Q4	$204K	Buy	+54,400	New	+$792K	0.02%	174
2020 Q1	–	Sell	-6,000	Closed	-$2K	–	416
2019 Q4	$2K	Buy	+6,000	New	+$55.3K	﹤0.01%	428

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

MAM

Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Cowen and Company's AUPH Position: Q2 2021 in Review

Cowen and Company sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2021, closing a stake of 20,776 shares — an estimated $265K sold.

Cowen and Company first reported a position in AUPH in Q1 2021 and held it in 1 quarter. The position peaked at $270K in Q1 2021. 167 funds tracked by Wall St. Rank hold AUPH as of Q2 2021.

Cowen and Company reported no remaining Aurinia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Cowen and Company sold 20,776 Aurinia Pharmaceuticals shares in Q2 2021, an estimated $265K.
Cowen and Company first reported a position in Aurinia Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Cowen and Company's Aurinia Pharmaceuticals position peaked at $270K in Q1 2021.
167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2021.

Based on Cowen and Company's 13F filing for Q2 2021, filed 13 Aug 2021.